Price Alert

Anavex Life Sciences Corp... (AVXL)

NASDAQ: AVXL · Real-Time Price · USD

9.03

0.23 (2.67%)

At close: Oct 15, 2025, 3:59 PM

9.02

-0.11%

Pre-market: Oct 16, 2025, 04:32 AM EDT

2.67% (1D)

Bid	8.88
Market Cap	775.62M
Revenue (ttm)	n/a
Net Income (ttm)	-34.93M
EPS (ttm)	-0.57
PE Ratio (ttm)	-15.84
Forward PE	3.71
Analyst	Buy
Dividends	n/a

Ask	9.05
Volume	1,040,366
Avg. Volume (20D)	1,174,023
Open	8.80
Previous Close	8.79
Day's Range	8.66 - 9.08
52-Week Range	5.22 - 14.44
Beta	0.83
Ex-Dividend Date	n/a

About AVXL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AVXL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AVXL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+9.73%

Anavex Life Sciences shares are trading higher. Th... Unlock content with Pro Subscription

9 months ago

+8.21%

Anavex Life Sciences shares are trading higher after the company revealed the publication of its peer-reviewed oral blarcamesine Phase IIb/III data in the Journal of Prevention of Alzheimer's Disease.

News

1 week ago · seekingalpha.com

Anavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For Schizophrenia

Anavex Life Sciences Corp. reported positive phase 2 results for ANAVEX 3-71 in schizophrenia, showing improved biomarkers and strong safety. AVXL's ANAVEX 3-71 targets all three schizophrenia domains...

2 months ago · seekingalpha.com

Anavex Life Sciences Corp. (AVXL) Q3 2025 Earnings Call Transcript

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Christopher U. Missling - President, CEO, Secretary & Director Clint Tomlinso...